Table 1 |
|||
|
Examples of diseases caused by loss of or ectopic function of the HH-GLI signaling pathway, and the possible agents that could, in principle, be used as therapeutics |
|||
|
Disease type |
Potential therapeutic |
||
|
|
|
||
|
Gain-of-function: |
Basal cell carcinoma |
Antagonist: |
Anti-HH antibodies |
|
Medulloblastoma |
Forskolin |
||
|
Rhabdomyosarcoma |
Cyclopamine |
||
|
Cur61414 |
|||
|
GLI repressors |
|||
|
Loss-of-function: |
Holoprosencephaly |
Agonist: |
SHH |
|
Hh-Ag* |
|||
|
|
|||
|
*Hh-Ag is the Hh agonist described by Frank-Kamenetsky et al.[1]. |
|||
|
Stecca and Altaba Journal of Biology 2002 1:9 doi:10.1186/1475-4924-1-9 |
|||